Therapeutic compositions

A formulation of ingenol angelate for use in therapy, comprising ingenol angelate which has been dissolved in a pharmaceutically acceptable, aprotic solvent, said formulation further comprising a pharmaceutically acceptable acidifying agent which is at least partially compatible with said solvent and which provides said formulation with an apparent pH of no greater than 4.5.

A method for the treatment of a skin cancer comprising applying to said skin cancer a formulation of ingenol angelate, said formulation comprising ingenol angelate which has been dissolved in a pharmaceutically acceptable aprotic solvent, said formulation further comprising a pharmaceutically acceptable acidifying agent which is at least partially compatible with said solvent and which provides said formulation with an apparent pH of no greater than 4.5.

A process for preparing a formulation of ingenol angelate, comprising dissolving said ingenol angelate in a pharmaceutically acceptable, aprotic solvent, said process comprising the addition of a pharmaceutically acceptable acidifying agent which is at least partially compatible with said solvent and which provides said formulation with an apparent pH of no greater than 4.5, said acidifying agent being added with, before, or after said ingenol angelate.